Hot-Stock für Kurzentschlossene: 140 % Belohnung
Seite 5 von 8 Neuester Beitrag: 13.05.16 22:22 | ||||
| Eröffnet am: | 25.03.10 18:55 | von: storm 30001. | Anzahl Beiträge: | 178 |
| Neuester Beitrag: | 13.05.16 22:22 | von: CosmicTrade | Leser gesamt: | 40.990 |
| Forum: | Börse | Leser heute: | 29 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | 3 | 4 | | 6 | 7 | 8 > | ||||
Denke das der Krus sehr günstig ist. die talfahrt ist nicht so dratisch wie sie sich in unserem Kurs niederspiegelt.
Denke das es heute um 15:30 schon wieder ein stück nach oben geht.
Optionen
| Boardmail an "Kostolanys Erbe" |
Wertpapier: WaferGen Biosystems |
chart_week_wafergenbiosystems.png (verkleinert auf 93%)
Ist immer so gelaufen die letzten Wochen. Es sei denn hier kamen vorher irgendwelche Abenteuerlichen News
WaferGen Bio-systems Inc. lost $4.5 million in the March quarter, up from a loss of $1.8 million in the first quarter a year earlier.
The Fremont business (OTCBB: WGBS) makes technology used in genetic analysis and biology research.
It had revenue of $389,785 in the March quarter, up from revenue of $41,838 in the same quarter a year earlier.
WaferGen sells both laboratory equipment and biology analysis chips used in the devices: a “razor and razor blade” business model, as it describes it.
In October, WaferGen signed a lease on a new head office in Fremont. Though it didn’t owe any rent for the first six months, the lease, which runs through April 2015, will ultimately cost it about $2.2 million total, plus maintenance fees.
At quarter’s end, WaferGen had accumulated a deficit of $35 million.
The company expects to keep losing money this year. It will also spend more on selling and administration as it ramps up to sell its products.
Alnoor Shivji is chairman and CEO of WaferGen.
Einnahmen
Der Umsatz für das erste Quartal zum 31. März 2010 betrug $ 389.785 gegenüber $ 41.838 für das erste Quartal 2009. Für das Quartal zum 31. März 2010, 67 Prozent des Umsatzes im Zusammenhang mit der SmartChip Real-Time PCR-Systeme für Kunden, die Teil der SmartChip Early-Access-Programm initiiert werden im Laufe des Quartals.
Das Unternehmen ist in den frühen Phasen der Vermarktung der SmartChip Real-Time PCR-System, und ist derzeit mit dem System und der SmartChip SmartChip Gene Expression Profiling Services als Teil ihrer Einnahmen schaffende Early-Access-Programm. Die SmartChip System umfasst die 5.184-Assay SmartChip, die SmartChip Cycler und SmartChip Nanodispenser oder Multi-Sample-Dispenser für die Untersuchung von Kandidatengenen und microRNA Tafeln für assoziierte Veränderungen innerhalb der Krankheit. Die SmartChip Gene Expression Profiling-Services sind an Universitäten vorgesehen, Forschung Krankenhäuser, pharmazeutische und biotechnologische Unternehmen von WaferGen Wissenschaftler der neue Unternehmenszentrale Werk in Fremont, Kalifornien
"Diese ersten Einnahmen aus dem SmartChip Early-Access-Programm ist ein Indiz für die Anerkennung der SmartChip System von führenden Universität, des Klinikums und der Biotechnologie und pharmazeutischen Forschern in den USA, Europa und Japan", sagte Alnoor Shivji, Chairman und CEO. "Angesichts unseres Geschäftsmodells sind wir mit dieser Basis, auf denen unser Geschäft aufzubauen SmartChip zu freuen."
WaferGen beschäftigt ein Geschäftsmodell, dass die Einnahmen generiert sowohl aus dem Verkauf der Instrumente und eine wiederkehrende Einnahmen aus dem Verkauf der SmartChip, ähnlich dem "Rasierer und Rasierklingen"-Geschäftsmodell. Darüber hinaus ist das Unternehmen auf Einnahmen durch das Angebot Service für Gen-expression profiling von Tausenden von Genen mit Hilfe der SmartChip System in-house.
Net Loss
WaferGen meldete einen Nettoverlust von $ 4.600.000, oder $ (0,14) je Aktie für das erste Quartal 2010 im Vergleich zu einem Nettoverlust von $ 1.800.000, oder $ (0,07) pro Aktie, gegenüber dem gleichen Zeitraum in 2009. Der Nettoverlust stieg ist vor allem auf einen unrealisierten Verlust von $ 1.900.000 auf den Fair Value von rund 3,5 Millionen ausstehenden Optionsscheine entfielen als derivative Verbindlichkeiten, vor allem getrieben durch eine deutliche Steigerung des Aktienkurses im Quartal. Das Unternehmen Forschung und Entwicklung stiegen um $ 0.600.000 auf die Entwicklung und Scale-up der SmartChip System. Verkauf und Marketing von 0.100.000 $ durch höhere Personalkosten und allgemeinen und Verwaltungskosten erhöhten stieg um $ 0.300.000, aufgrund der erhöhten Personalkosten, vor allem für Führungskräfte und Berater, sowie ein Umzug in eine neue Zentrale Anlage mit zusätzlichen Labor-und Büroflächen space.
Aktiva
Das Unternehmen beendete das Quartal mit $ 4.900.000 in der Bilanzsumme, einschließlich Bargeld in Höhe von 3.600.000 $, sowie das Betriebskapital von $ 2.100.000. Das Unternehmen endete 2009 mit $ 6.900.000 an der Bilanzsumme und Betriebskapital in Höhe von $ 4.200.000, nachdem generiert mehr als 11.000.000 $ in 2009 durch die Finanzierung von Aktivitäten und $ 379.373 von Total 2009 Einnahmen.
Ersten Quartal und frühen zweiten Quartal 2010 Erfolge Jumpstart Full-Scale SmartChip Verfügbarkeit
"Während des ersten Quartals und frühen zweiten Quartal haben wir hervorragende Fortschritte gemacht, um für volle Verfügbarkeit unserer SmartChip System in der zweiten Jahreshälfte 2010 vorzubereiten", sagte Shivji.
"Zuerst schlossen wir die Entwicklung der SmartChip System (5184 Brunnen), die den Wissenschaftlern ermöglichen, um Tausende von Genen gleichzeitig auf Gen-spezifische Signalwege Studie, was möglicherweise zur Ermittlung und Validierung von klinisch relevanten Krankheit Signaturen werden. Im April haben wir die Multi SmartChip -Probengeber zu ermöglichen erhebliche Geschwindigkeits-und Kostenvorteile für die Biomarker-Validierung mittels Genexpression und Genotypisierung.
"Weiter, starteten wir das Early-Access-Programm, dass das Anbieten der SmartChip Service, dass wir anschließend mit der Zugabe des Human microRNA Panel für Genexpressionsanalysen verbessert. Dieses Programm führte in zehn führenden großen Universitäten und Service Provider-Kunden enthalten.
"Zur Vorbereitung für groß angelegte Kommerzialisierung der SmartChip System haben wir unsere Fertigungskapazität erhöht, um uns zu 10.000 Chips pro Jahr produzieren. Wir stärken unsere Vertriebs-und Marketing-Fähigkeiten mit der Ernennung der Industrie-Veteran Janet Lankard als Senior Vice President, Worldwide Sales and zu unterstützen. Darüber hinaus erhielten wir CE-Kennzeichnung und TÜV-Zertifizierung die Sicherheit unserer SmartChip Cycler und SmartChip Nanodispenser, dass es uns ermöglichen, vermarkten und verkaufen die SmartChip System in Europa und Japan, wo das CE-Zeichen erkannt werden. Wir erweitern unser Programm in Zusammenarbeit mit Europa Zugabe von der Universität Gent, da beide ein Kollaborateur und Early-Access-Kunden, wir haben eine Vereinbarung unterzeichnet mit der Regierung in Richtung Luxemburg über unser europäisches Hauptquartier, und wir zogen in eine neue weltweite Zentrale Einrichtung für Wachstum zu bewältigen. "
Das Unternehmen Marketing-Aktivitäten durchgeführt, um SmartChip zu BioPharma präsentieren Unternehmen bei wichtigen Konferenzen, die im ersten Quartal und Anfang des zweiten Quartals sind die Cambridge Healthcare Instituts 17. Internationale Molecular Medicine Tri-Conference, der Verband der Biomolekulare Resource Einrichtungen (ABRF); microRNA in Human Disease & Development; American Association of Cancer Research (AACR), und die Biomarker World Congress
An der Cambridge Healthcare Institute's Conference im Februar 2010 das Unternehmen auch Daten über die Leistung der SmartChip System vorgestellt. Die Präsentation Plakat enthalten einen Überblick über das Unternehmen neuartige gesamten Genoms, High-Throughput-SmartChip Real-Time PCR System und Daten auf die Fähigkeit des Systems zur Genexpression durch Echtzeit-Quantifizierung von PCR für eine große Anzahl von Genen auf einmal nutzen demonstrieren einen einfachen Workflow. WaferGen's Oncology SmartChip Human Gene Panel wurde verwendet, um Veränderungen in der Genexpression in Brust-und Lungentumoren zu quantifizieren.
Ziele für 2010
"Für eine vollständige Kommerzialisierung der SmartChip System im Jahr 2010, sind wir weiterhin auf mehrere wichtige Ziele der Arbeit", fuhr Shivji. "Da wir mit erheblichen Aufwendungen Abschluss der Kommerzialisierung des SmartChip Produktlinie entstehen erwarten, planen wir eine zusätzliche Finanzierung zu sichern. Ein Teil dieser Mittel wird verwendet, um Scale-up Instrument Fertigungskapazität auf 1-2 pro Woche. Um Vorverkauf in der EU und Japan planen wir, Vereinbarungen mit europäischen und japanischen Händler unterzeichnen und offene europäische Zentrale Einrichtung. Wir planen auch die Early Access Program-Kundenstamm durch die Konzentration auf die Zugabe von mehr Biopharma-Unternehmen ausbauen. Zur Unterstützung unserer laufenden Kommerzialisierung und FuE-Aktivitäten planen wir, zusätzliche Mitglieder zu unserem Wissenschaftlichen Beirat und Branchenveteranen fügen dem Board of Directors.
"Dies ist eine sehr spannende und bedeutendes Jahr für WaferGen und für Forscher, die Genom-Analyse durchführen", schloss Shivji. "Pharma-und Biotech-Unternehmen ausgegeben wird, ca. 65200000000 $ in 2008 für Forschung und Entwicklung für neue Wirkstoffforschung. Wir glauben, dass viele dieser Bemühungen neue Therapeutika zu suchen, und dass dieser Ausgaben viel wird auf die Entwicklungen auf molekularer Ebene für das Verständnis der gerichtet werden Expression spezifischer DNA-Segmente (oder Gene). Durch unsere SmartChip Real-Time PCR System, indem es Forschern sind wir in neu zu definieren Performance-Standards mit erheblichen Zeit-und Kosteneinsparungen in den Bereichen Pharmakogenomik und personalisierte Medizin (die Studie, wie Gene Auswirkungen auf die Individuen reagieren auf Medikamente). "
WaferGen Biosystems, Inc. ist ein Marktführer in der Entwicklung, Herstellung und Vertrieb von state-of-the-art-Systeme für die Genomanalyse für die Life Science-und Pharmaindustrie. Das Unternehmen bietet derzeit seine neue innovative kostenpflichtigen Dienst für Gen-expression profiling ", während weiterhin aktiv zu vermarkten SmartChip Real-Time PCR System, dass eine Genexpression real-time PCR-Plattform für die Genexpression und Genotypisierung Märkten ist. Kombiniert mit der nächsten Generation Chemie und optimiert Assays durch WaferGen unter der Leitung von David Gelfand, Ph.D., Chief Scientific Officer und einer der Pioniere der PCR, dieses innovative System entwickelt, verspricht erhebliche Geschwindigkeits-und Kostenvorteile für Forscher liefern in die Genexpression und Genotypisierung Märkten.
Basierend auf Kooperationen mit führenden Forschungseinrichtungen gegründet, glaubt, dass die WaferGen SmartChip Real-Time PCR-System als Plattform der Wahl für die Biomarker-Identifizierung und Validierung positioniert ist. Das System wird eine Reihe von wichtigen Mühelosigkeit-of-use Features, einschließlich Content-ready-Chips mit Gen-Panels für microRNA, Krebs und ganzer Genome optimiert. WaferGen glaubt, dass die SmartChip Real-Time PCR-System wird die erste Plattform, um die High-Throughput-Leistungsfähigkeit und Kosteneffizienz der bestehenden Microarrays kombiniert werden, wobei die Empfindlichkeit und Genauigkeit der real-time PCR.
http://www.auto-mobi.info/...amp;task=view&id=28338&Itemid=56
Optionen
| Boardmail an "storm 300018" |
Wertpapier: WaferGen Biosystems |
Momentan minus 18 % in USA
Optionen
| Boardmail an "Kostolanys Erbe" |
Wertpapier: WaferGen Biosystems |
chart_intraday_wafergenbiosystems.png (verkleinert auf 93%)
Optionen
| Boardmail an "Kostolanys Erbe" |
Wertpapier: WaferGen Biosystems |
Optionen
| Boardmail an "storm 300018" |
Wertpapier: WaferGen Biosystems |
04-08 Juni, 2010 | McCormick Place | Chicago, Illinois
2010 ASCO Annual Meeting Press Kit |
http://www.asco.org/ASCOv2/Press+Center/...O+Annual+Meeting+Press+Kit |
Optionen
| Boardmail an "storm 300018" |
Wertpapier: WaferGen Biosystems |
FREMONT, Calif., June 8 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board:WGBS.ob - News), a leading developer of state-of-the-art genome analysis systems, today announced the signing of an exclusive distribution agreement for the company's SmartChip Real-Time PCR System with Takeda Rika Kogyo Co., Ltd., a leading distributor of innovative products and services in the life science markets within Japan.
"Distribution of the SmartChip System to customers in Japan is an important step of our commercialization strategy to expand customer adoption of the SmartChip System into new large target markets," said Alnoor Shivji, chairman and CEO of WaferGen. "We look forward to a continued strong relationship with Takeda Rika Kogyo to enable the success of SmartChip in the important Japanese market."
"We recognize the value of the SmartChip System to advance genome analysis research in the growing Japanese market, and are so confident in its value that we have committed to a sales agreement with WaferGen," said Takuto Takeda, president of Takeda Rika Kogyo. "By improving biomarker identification and validation, we believe that the SmartChip System will make a significant difference by enabling scientists to more quickly and effectively understand disease at the molecular level in order to target therapies."
The SmartChip Real-Time PCR System is a genome analysis platform that combines the high-throughput capability and cost efficiencies of existing microarrays, with the sensitivity and accuracy of real-time PCR, offering identification and validation capability in a single platform. The result will be the ability to conduct improved gene expression research at a fraction of the time and cost currently produced by existing instrument systems. The WaferGen SmartChip System will provide a number of key ease-of-use features including content-ready chips with gene panels optimized for microRNA, cancer, and whole genome.
The company is in the early stages of commercializing the SmartChip System, and is currently offering the SmartChip System and the SmartChip Gene Expression Profiling Services as part of its revenue-generating Early-Access Program. The SmartChip System includes the 5,184-assay SmartChip, the SmartChip Cycler, and SmartChip Nanodispenser or Multi-Sample Nanodispenser for investigating candidate genes and microRNA panels for associate changes within disease states. The SmartChip Gene-Expression Profiling Services are provided to universities, research hospitals, pharmaceutical and biotechnology companies by WaferGen scientists at the company's headquarters facility in Fremont, Calif.
About Takeda Rika Kogyo
Takeda Rika Kogyo, founded in 1948, is a leading distributor in Japan, providing researchers in academic institutes and industry with innovative technological solutions. Takeda offers a wide variety of unique scientific products from multiple suppliers through its distribution channels developed by its experienced marketing team. Takeda Rika Kogyo is aggressively investing its resources into development of the life science field to use its capabilities to bring state-of-the-art technologies from countries outside Japan to leading Japanese scientists.
About WaferGen
WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for genome analysis for the life science and pharmaceutical industries. Based on collaborations established with leading research institutions, WaferGen believes that the SmartChip Real-Time PCR System is positioned as the platform of choice for biomarker identification and validation. Combined with next-generation chemistry and optimized assays being developed by WaferGen under the guidance of David Gelfand, Ph.D., Chief Scientific Officer and one of the pioneers of PCR, this innovative system promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets.
Forward-Looking Statements
This press release contains certain "forward-looking statements". Such statements include statements relating to the expected benefits to the company of the distribution agreement with Takeda Rika Kogyo and the distribution of the SmartChip System in Japan, the expected benefits and advantages of the SmartChip technology to gene expression research and other applications, the expected throughput levels of the SmartChip Real-Time PCR System,, and other statements relating to future events or to the company's future financial performance and are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words.
Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that: (i) the company may be unsuccessful in commercially developing its products or in achieving market acceptance of new and relatively unproven technologies; (ii) the company will need to raise additional capital to meet its business requirements in the future and the company may not be able to do so on reasonable terms or at all; (iii) the company's proprietary intellectual property rights may not adequately protect its products and technologies; and (iv) the company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2009 and the Form 10Q for the quarter ended March 31, 2010. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Contact: | |
WaferGen | |
Mona Chadha | |
mona.chadha@wafergen.com | |
Or | |
Joyce Strand | |
joyce.strand@wafergen.com | |
510-651-4450 |
WaferGen Announces Two Gene Expression Profiling Panels for SmartChip Real-Time PCR System for High Throughput, Cost-Effective Biomarker Discovery and Validation
Fremont, Calif., June 10, 2010 -- WaferGen Biosystems, Inc. (OTCBB:WGBS), a leading developer of state-of-the-art genetic analysis systems, today announced the availability of two gene expression profiling panels for the SmartChip Real-Time PCR System that will enable microRNA and cancer pathway profiling capability.
By querying up to a thousand genes in a single sample, these panels enable discovery and validation of biomarkers in a high-throughput, highly cost-effective manner. Recently available only with the SmartChip Gene Expression Profiling Services provided by WaferGen scientists at the company's headquarters facility in Fremont, Calif., the two panels are now available for use by customers on the commercial SmartChip System.
"By offering these panels to researchers and scientists, we broaden the applicability of the SmartChip System across a spectrum of research needs, thereby expanding its market potential," said Alnoor Shivji, chairman and CEO, WaferGen.
The first panel is the SmartChip Human MicroRNA Panel that provides a comprehensive human microRNA profile of more than 800 microRNAs on a single SmartChip and is for use with RNA from cell lines, frozen tissue and formalin fixed paraffin embedded tissue (FFPE), one of the more difficult-to-work-with samples. The second panel is the SmartChip Human Oncology Gene Panel that provides approximately 1000 genes on a single chip for gene expression profiling for oncology in four replicates including representative kinases, cell cycle proliferation genes, signal transduction genes, apoptosis genes, DNA repair genes, and G-protein coupled receptors.
"The identification of tumor-specific molecular alterations has provided researchers and clinicians with new tools to characterize, based on gene expression patterns, the critical pathways regulating tumor growth. More exciting is the promise of less toxic, more effective targeted therapies. WaferGen's novel panels promise to enable researchers to evaluate the full spectrum of validated cancer biomarkers in one pass with higher fidelity than existing technologies, and at a cost that even small academic labs can afford," said Christopher Sears, PhD, Chief Scientific Officer at Ambergen, who has held joint academic appointments in the field of oncology at Children's Hospital Boston, The Broad Institute, Harvard Medical School and the Dana Farber Cancer Institute, and is a member of WaferGen's Scientific Advisory Board.
"MicroRNAs and cancer pathways are both key determinants of clinical cancer behaviors, and measuring these is critically important for fundamental cancer research and for the development of clinically useful biomarkers for diverse cancer types. The addition of microRNA and oncology gene expression panels to the WaferGen SmartChip System enables analysis of critical molecular signatures for cancer in a highly efficient and cost-effective manner," said Muneesh Tewari, M.D., Ph.D., faculty member at Fred Hutchinson Cancer Research Center and a recently added member of WaferGen's Scientific Advisory Board. Since joining the Hutchinson Center in 2005, Tewari has focused on studying the role of microRNAs in cancer, as well as on developing microRNA-based biomarker approaches for oncology. Prior to this, Dr. Tewari served in faculty and clinical positions at Harvard Medical School, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Massachusetts General Hospital.
The 5,184 nano-well SmartChip uses a small amount of biological material to query either a thousand genes in a single sample, or fewer genes on many samples, enabling a workflow from discovery to validation of biomarkers while saving researchers time. By applying Quantitative Real-Time PCR Expression Profiling, the SmartChip System combines the gene expression profiling throughput of microarrays with the sensitivity, precision and dynamic range of Real-Time PCR, the gold standard of gene expression studies. The 27 built-in controls in the Human Oncology Gene Panel and the 12 built-in controls in the Human MicroRNA Panel offer added quality assurance to the results.
The company is in the early stages of commercializing the SmartChip System, and is currently offering the SmartChip System and the SmartChip Gene Expression Profiling Services as part of its revenue-generating Early-Access Program. The SmartChip System includes the 5,184-assay SmartChip, the SmartChip Cycler, and SmartChip Nanodispenser or Multi-Sample Nanodispenser. The SmartChip Gene Expression Profiling Services are provided to universities, research hospitals, pharmaceutical and biotechnology companies by WaferGen scientists at the company's headquarters facility in Fremont, Calif.
MicroRNAs
MicroRNAs are small non-protein-coding single-stranded RNA molecules of 21-23 nucleotides in length that function as negative regulators of gene expression by targeting specific messenger RNAs. This either inhibits translation or promotes messenger RNA degradation. Cancer diagnosis, prognosis, and treatment are important potential clinical applications of microRNA profiling. The SmartChip Human microRNA panel will use more than 800 human genes from the new miRBase version 14.0 sequence database.
About WaferGen
WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for genome analysis for the life science and pharmaceutical industries. Based on collaborations established with leading research institutions, WaferGen believes that the SmartChip Real-Time PCR System is positioned as the platform of choice for biomarker identification and validation. Combined with next-generation chemistry and optimized assays being developed by WaferGen under the guidance of David Gelfand, Ph.D., Chief Scientific Officer and one of the pioneers of PCR, this innovative system promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets.
Forward-Looking Statements
This press release contains certain "forward-looking statements". Such statements include statements relating to the expected benefits and advantages of the SmartChip microRNA and Oncology panels, the expected benefits and advantages of the SmartChip service for gene-expression research, the expected benefits and advantages of the SmartChip technology to other applications, the expected throughput levels of the SmartChip Real-Time PCR System, and other statements relating to future events or to the company's future financial performance and are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words.
Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that: (i) the company may be unsuccessful in commercially developing its products or in achieving market acceptance of new and relatively unproven technologies; (ii) the company will need to raise additional capital to meet its business requirements in the future and the company may not be able to do so on reasonable terms or at all; (iii) the company's proprietary intellectual property rights may not adequately protect its products and technologies; and (iv) the company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2009 and the Form 10Q for the quarter ended March 31, 2010. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
so langsam sollte wieder mal eine andere richtung eingeschlagen werden
wann ist hier mit ersten positiven vertriebsergebnissen zu rechnen?
oder ist etwas gravierendes passiert, was diese kurse rechtfertigt ?
WaferGen Announces Kyoto University to Use SmartChip Real-Time PCR System to Identify and Compare Biomarkers to Advance Regenerative Tissue Research
Fremont, Calif., June 17, 2010 -- WaferGen Biosystems, Inc. (OTCBB:WGBS), a leading developer of state-of-the-art genetic analysis systems, today announced that scientists from Kyoto University will use the WaferGen SmartChip Real-Time PCR System to identify and compare biomarkers to advance their research to regenerate tissues such as bone, cartilage, and muscle, lost or reduced due to various causes. Kyoto University is one of ten early-access customers using the SmartChip platform to advance research results through the improved discovery and validation of biomarkers enabled by its high-throughput capability.The researchers at Kyoto University are led by Professor Shinya Yamanaka, M.D., Ph.D., Director of Kyoto University’s Center for iPS Cell Research and Application (CiRA), and a recent recipient of both the Imperial Prize as well as the Japan Academy Prize. They are using the SmartChip platform to better identify and compare biomarkers, important to the clarification of iPS cells.
“We are pleased that a university of the stature of Kyoto - in existence for more than 100 years with more than 22,000 students today - has chosen our SmartChip System as part of their ground-breaking research project,” said Alnoor Shivji, chairman and CEO, WaferGen. “By providing both the discovery and validation of biomarkers on one platform, SmartChip enables more extensive gene analysis, a key component in the advancement of important new therapies such as regenerative treatments.”
About WaferGen and the SmartChip Real-Time PCR System
WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for genetic analysis for the life science and pharmaceutical industries. The company currently offers its innovative fee-based service for gene-expression profiling, while continuing the early commercialization of its SmartChip Real-Time PCR System that is designed as the first whole genome, high-throughput gene expression real-time PCR platform for the gene expression and genotyping markets. The initial product on the SmartChip platform is the proprietary SmartChip Human Oncology Gene Panel that provides pathway based gene expression profiling for Oncology. In addition, the SmartChip Human microRNA Panel provides a comprehensive panel of over 800 microRNAs on a single SmartChip to enable discovery of disease specific microRNAs
Combined with next-generation chemistry and optimized assays being developed by WaferGen under the guidance of David Gelfand, Ph.D., Chief Scientific Officer and one of the pioneers of PCR, this innovative system promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets.
Based on collaborations established with leading research institutions, WaferGen believes that the SmartChip Real-Time PCR System is positioned as the platform of choice for biomarker discovery and validation. The system will provide a number of key ease-of-use features including content-ready chips with gene panels optimized for microRNA, cancer, and whole genome. WaferGen believes the SmartChip Real-Time PCR System will be the first platform to combine the high-throughput capability and cost efficiencies of existing microarrays, with the sensitivity and accuracy of real-time PCR.
Forward-Looking Statements
This press release contains certain "forward-looking statements". Such statements include statements relating to the expected benefits and advantages of the SmartChip service for gene-expression research, the expected benefits and advantages of the SmartChip technology to other applications, the expected throughput levels of the SmartChip Real-Time PCR System and other statements relating to future events and are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words.